Our paper on KRAS-Ago2 interaction featured by the NCI, Science daily and Science (Editor’s choice)

KRAS gets the silencing treatment

graphical abstract

Mutations in the KRAS protooncogene drive the growth of some of the most lethal human tumors, including pancreatic and lung cancers. Efforts to pharmacologically inhibit KRAS itself, or components of its well-studied signaling pathway, have been largely unsuccessful. Shankar et al. considered the possibility that KRAS may have additional uncharacterized roles that contribute to tumor development and that may be more susceptible to drug treatment.

Science (Editor’s choice)

Science Daily article

NCI- A conversation with Arul Chinnaiyan